eplontersen: Clinical Trials

5 trials of eplontersen, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 completed, 1 enrolling by invitation. 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 35Active not recruiting 2, Completed 2, Enrolling by invitation 1

Follow eplontersen: new trials by email Literature Review of eplontersen trials Research Report on eplontersen

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
Eplontersen, Placebo - Transthyretin Amyloid Cardiomyopathy
Phase 3Active not recruitingAstraZeneca642023-12-012026-11-06
An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Eplontersen - Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Phase 3Enrolling by invitationIonis Pharmaceuticals, Inc.14002022-11-302026-04-17
A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Eplontersen - Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Phase 3Active not recruitingIonis Pharmaceuticals, Inc.1512022-01-042025-12-04
CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Eplontersen, Placebo - Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Phase 3CompletedIonis Pharmaceuticals, Inc.14382020-03-132026-09-03
NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Inotersen, Eplontersen - Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
Phase 3CompletedIonis Pharmaceuticals, Inc.1682019-12-112024-12-13

Conditions studied

Amyloidosis (3)  ·  Cardiomyopathies (1)  ·  Polyneuropathies (1)

Sponsors

Ionis Pharmaceuticals, Inc. (4)  ·  AstraZeneca (1)

Countries

Argentina (4)  ·  Australia (4)  ·  Brazil (4)  ·  Canada (4)  ·  France (4)  ·  Italy (4)  ·  Portugal (4)  ·  Spain (4)  ·  Sweden (4)  ·  United States (4)  ·  Germany (3)  ·  Greece (3)  ·  Austria (2)  ·  Belgium (2)  ·  Cyprus (2)

Top investigators

Shuyang Zhang, MD (1)

Results publications

PMID 38065307, PMID 33638113, PMID 36525140, PMID 37768671, PMID 41913562, PMID 41937511, PMID 42104840, PMID 42663301, PMID 42669065, PMID 42742182

NIH funding

2019 (2)